# Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

> **NCT05156892** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Anthony Joshua, FRACP** · enrollment: 44 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** SUBA-itraconazole
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT05156892
- **Lead sponsor:** Anthony Joshua, FRACP
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-04
- **Primary completion:** 2026-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156892, "Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05156892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*